drug · small molecule

INLURIYO

updated 5mo ago

by $LLY ELI LILLY & Co🔗 ChEMBL

community read0 votes

🐶 often sniffed alongside

top 4

Small molecule drug with a maximum clinical stage of Unknown, with 1 investigational indication.

all catalysts(0)

nothing on the calendar yet

News(4)

An orexin drug’s ‘proof-of-concept’ in ADHD; Cue’s ‘unwarranted’ share slide
Alkermes’ results heightened anticipation for a coming readout in 2027. Elsewhere, AbbVie leaned into AI drug discovery and the FDA expanded use of Eli Lilly’s breast cancer pill.
biopharma_dive · 8d ago
FDA approves Lilly's oral SERD combo for second-line breast cancer therapy
The FDA approved a new combination regimen from Eli Lilly for certain breast cancer patients, one that includes Lilly’s oral selective estrogen receptor degrader (SERD) drug Inluriyo. Patients with…
endpoints · 12d ago
FDA approves AstraZeneca’s Etcamah, opening ctDNA-guided treatment paradigm in breast cancer
In a rare divergence from its own expert panel, the FDA has granted accelerated approval to AstraZeneca’s camizestrant, turning a contentious regulatory review into a landmark win that opens a new…
fiercebiotech · 22d ago
Arvinas, Pfizer find new partner for ‘Protac’ breast cancer drug
A deal with Rigel Pharmaceuticals ends months of uncertainty about the future of Veppanu, a first-of-its-kind, newly approved medicine with a murky financial outlook.
biopharma_dive · 4mo ago

brand

INLURIYO

generic

IMLUNESTRANT TOSYLATE

MOA

12.1 Mechanism of Action Imlunestrant is an estrogen receptor (ER) antagonist that binds to ERα. In vitro, imlunestrant induced degradation of ERα, leading to inhibition of ER-dependent gene transcription and cellular proliferation in ER+ breast cancer cells. Imlunestrant demonstrated in vitro and in vivo anti-tumor activity in ER+ breast cancer xenograft models, including models with ESR1 mutations.

indication

1 INDICATIONS AND USAGE INLURIYO is indicated for the treatment of adults with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative, estrogen receptor-1 ( ESR1 )-mutated advanced or metastatic breast cancer with disease progression following at least one line of endocrine therapy. INLURIYO TM is an estrogen receptor antagonist indicated for: treatment of adults with ER-positive, HER2-negative, ESR1 -mutated advanced or metastatic breast cancer with disease progression following at least one line of endocrine therapy ( 1 )

Data sources

ClinicalTrials.gov · OpenTargets

last refreshed 2h ago

Found something off?

comments(0)

5-min edit window · permanent after that

no comments yet — first sniff?

News(4)

An orexin drug’s ‘proof-of-concept’ in ADHD; Cue’s ‘unwarranted’ share slide

Alkermes’ results heightened anticipation for a coming readout in 2027. Elsewhere, AbbVie leaned into AI drug discovery and the FDA expanded use of Eli Lilly’s breast cancer pill.

biopharma_dive · 8d ago

FDA approves Lilly's oral SERD combo for second-line breast cancer therapy

The FDA approved a new combination regimen from Eli Lilly for certain breast cancer patients, one that includes Lilly’s oral selective estrogen receptor degrader (SERD) drug Inluriyo. Patients with…

endpoints · 12d ago

FDA approves AstraZeneca’s Etcamah, opening ctDNA-guided treatment paradigm in breast cancer

In a rare divergence from its own expert panel, the FDA has granted accelerated approval to AstraZeneca’s camizestrant, turning a contentious regulatory review into a landmark win that opens a new…

fiercebiotech · 22d ago

Arvinas, Pfizer find new partner for ‘Protac’ breast cancer drug

A deal with Rigel Pharmaceuticals ends months of uncertainty about the future of Veppanu, a first-of-its-kind, newly approved medicine with a murky financial outlook.

biopharma_dive · 4mo ago

INLURIYO

🐶 often sniffed alongside

all catalysts(0)

News(4)

Report a data issue

comments(0)

INLURIYO

🐶 often sniffed alongside

all catalysts(0)

News(4)

Report a data issue

comments(0)